Literature DB >> 3406051

Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study.

L Ambrozi1, W Danielczyk.   

Abstract

Memantine was investigated in a phase II double-blind trial on 30 elderly patients by comparison with a placebo with the aid of several psychometric tests. It was found that vigilance, short-term memory, and concentration improve significantly under Memantine. It was also found that Memantine exerted a beneficial effect on psychiatric and neurological symptoms despite the presence of an organic psychosyndrome of many years' duration and multiple morbidity. The tolerance of the preparation was good in virtually all cases and a gradually increasing dosage is recommended. On the basis of these findings the authors assume that the therapeutic efficiency can be confirmed in a phase III trial.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3406051     DOI: 10.1055/s-2007-1014666

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

Review 1.  Memantine.

Authors:  Blair Jarvis; David P Figgitt
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 2.  Glutamate: its role in learning, memory, and the aging brain.

Authors:  W J McEntee; T H Crook
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.

Authors:  Thomas Müller; Paul Foley
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

4.  N-methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity.

Authors:  Payman Nasr; Timothy Carbery; James W Geddes
Journal:  Neurochem Res       Date:  2008-08-08       Impact factor: 3.996

5.  Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study.

Authors:  M I Botez; T Botez-Marquard; R Elie; O L Pedraza; K Goyette; R Lalonde
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

6.  Memantine for dementia.

Authors:  Rupert McShane; Maggie J Westby; Emmert Roberts; Neda Minakaran; Lon Schneider; Lucy E Farrimond; Nicola Maayan; Jennifer Ware; Jean Debarros
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

Review 7.  Safinamide: an add-on treatment for managing Parkinson's disease.

Authors:  Thomas Müller
Journal:  Clin Pharmacol       Date:  2018-04-05

Review 8.  Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.

Authors:  Sagari Bette; Danielle S Shpiner; Carlos Singer; Henry Moore
Journal:  Ther Clin Risk Manag       Date:  2018-09-18       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.